co About Clinical Research Study | SCiStar Study AST‐OPC1

About SCiStar Study

SCiStar is a clinical research study evaluating the safety and activity of AST-OPC1 oligodendrocyte progenitor cells, an investigational agent for newly injured people with sensorimotor cervical (in the neck) spinal cord injury. The SCiStar study will evaluate three increasing doses of AST-OPC1 administered at a single point in time between 21 and 42 days after injury. People who meet SCiStar study eligibility criteria will receive one of three AST-OPC1 doses as an injection in the spine.